CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)
SUZHOU, China, March 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced thatChina's National Medical Products Administration (NMPA) has approved the clinical trial application to begin a Phase 1 trial inChina for BLU-667 (CS3009), a highly selective and potent ...
CStone received IND approval in China for HDAC6 inhibitor CS3003
SUZHOU, China, March 13, 2019 /PRNewswire/ -- CStone Pharmaceuticals (Suzhou) Co., Ltd. ("CStone", stock code: 2616.HK) announced that the National Medical Products Administration (NMPA) recently approved company's histone deacetylase 6 (HDAC6) selective inhibitor CS3003 for Phase I clinical tria...
CStone Pharmaceuticals listed on the Hong Kong Stock Exchange today
HONG KONG, Feb. 26, 2019 /PRNewswire/ -- CStone Pharmaceuticals (Stock code: 2616) today announced the listing of 186,396,000 shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price ofHK$12.00 per share, the net proceeds to be received by the Company are aboutHK$2,085...
